# Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

> **NCT04699188** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 344 (actual)

## Conditions studied

- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Colorectal
- Cancer of Lung
- Cancer of the Lung
- Lung Cancer
- Neoplasms, Lung
- Neoplasms, Pulmonary
- Pulmonary Cancer
- Pulmonary Neoplasms

## Interventions

- **DRUG:** JDQ443
- **DRUG:** TNO155
- **BIOLOGICAL:** tislelizumab

## Key facts

- **NCT ID:** NCT04699188
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-24
- **Primary completion:** 2027-01-25
- **Final completion:** 2027-01-25
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699188, "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04699188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*